Niagen Bioscience Inc NAGE.OQ NAGE.O is expected to show a rise in quarterly revenue when it reports results on May 7 for the period ending March 31 2025
The Los Angeles California-based company is expected to report a 22.3% increase in revenue to $27.1 million from $22.15 million a year ago, according to the mean estimate from 3 analysts, based on LSEG data.
LSEG's mean analyst estimate for Niagen Bioscience Inc is for earnings of 2 cents per share.
The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 4 "strong buy" or "buy," no "hold" and no "sell" or "strong sell."
The mean earnings estimate of analysts was unchanged in the last three months.
Wall Street's median 12-month price target for Niagen Bioscience Inc is $8.05, above its last closing price of $8.00.
Previous quarterly performance (using preferred earnings measure in US dollars).
QUARTER ENDING | STARMINESMARTESTIMATE® | LSEG IBES ESTIMATE | ACTUAL | BEAT, MET, MISSED | SURPRISE % |
Dec. 31 2024 | 0.02 | 0.02 | 0.09 | Beat | 350 |
Sep. 30 2024 | 0.01 | 0.00 | 0.02 | Beat | 500.6 |
Jun. 30 2024 | -0.02 | -0.02 | 0.00 | Beat | 100 |
Mar. 31 2024 | -0.02 | -0.02 | -0.01 | Beat | 40 |
Dec. 31 2023 | -0.03 | -0.03 | 0.00 | Beat | 100 |
Sep. 30 2023 | -0.03 | -0.03 | -0.01 | Beat | 69.2 |
Jun. 30 2023 | -0.04 | -0.04 | -0.03 | Beat | 20 |
Mar. 31 2023 | -0.05 | -0.05 | -0.03 | Beat | 37.5 |
This summary was machine generated May 5 at 20:20 GMT. All figures in US dollars unless otherwise stated. (For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com)
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.